drugset / Trial / NCT00441012

Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)

NCT00441012

Phase 3 Completed 546 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindPrevention

Summary

To determine if there is an improvement in the immune response to HBsAg (hepatitis B virus) in healthy infants using a modified process in a combination Haemophilus Influenzae, type b/Hepatitis B vaccine and a currently licensed Haemophilus Influenzae, type b/Hepatitis B vaccine

Timeline

Start
2006-12
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Comvax Vaccine 0.5 ml
Subject Modified Process Vaccine Vaccine 0.5 ml